Compound 2 reacted distinctly less with a model DNA strand than Compound 1, DDP and OxPt in a laboratory comparison of four platinum compounds. It was the study’s clearest difference. The result was qualitative: the researchers did not report a numerical effect estimate.
The comparison did not stop at DNA. The researchers tested an 8mer oligonucleotide, Angiotensin I (AT1), and cytochrome c (CytC), using ESI-MS and MS/MS to examine platinum-containing biomolecular adducts and UV-Vis spectroscopy to examine changes in CytC. DDP and OxPt were reference substances.
How the comparison was made
These were isolated biomolecular models rather than a competitive mixture containing DNA, peptide and protein together. That design allowed the compounds to be compared in defined settings, but it could not show whether any compound would favor DNA over peptide or protein when all three were present at once.
For the DNA experiment, the platinum compound and oligonucleotide were combined at a 3:1 molar ratio. In ordinary terms, there were three units of platinum compound for every one unit of the DNA model. The mixtures were held at 37°C with gentle shaking at 200 rpm for 48 hours.
Samples were collected after 3, 6, 24 and 48 hours, diluted and passed through a filter with 0.22 μm pores before analysis. The repeated sampling let the researchers follow how platinum-containing products appeared over time, which was central to comparing reaction kinetics.
The mass-spectrometry work used positive- or negative-mode Orbitrap ESI-MS. For HCD MS/MS, ions were isolated within a 7 m/z window and the NCE setting was increased step by step. Apm 2 S or Aom 2 S was used to interpret selected fragments for possible binding-site information.
A clear difference, but not a precise map
Compound 2 showed distinctly lower reactivity toward the model oligonucleotide than Compound 1, DDP or OxPt. The analysis did not quantify the size of that difference, so the result does not say how many times slower or weaker the reaction was.
The researchers also looked for clues about where the compounds attached. Low-abundance MS/MS fragments from Compounds 1 and 2 pointed toward the two adjacent guanines in the oligonucleotide, but the evidence was limited and did not establish the binding site conclusively.
The authors attributed the differences among the complexes mainly to reaction kinetics. In practical terms, the contrast may reflect the speed and timing of the chemical steps rather than a confirmed difference in the DNA site involved. The study therefore provides a qualitative comparison, not a direct quantitative comparison of reaction rates or binding affinities.
The wider test still has important boundaries
Angiotensin I and CytC broadened the work beyond a DNA-binding experiment by providing peptide and protein models for comparison. The study examined how the four platinum compounds interacted with each model separately, using mass spectrometric evidence for biomolecular adducts and spectroscopic evidence for CytC changes.
A blank incubation containing only CytC in water was analyzed at each time point as a protein control. This control provided a reference for interpreting changes in the protein model during the incubation.
The findings should be read as mechanistic evidence from isolated models under simplified aqueous and mass-spectrometry-compatible conditions. They do not show preferential targeting in cells, animals or humans, and they do not establish anticancer activity, clinical efficacy or safety.
The study also leaves open whether the observed pattern would persist when biological conditions alter the compounds’ chemical forms and when DNA, peptide and protein compete with one another. It did not identify the actual molecular target, or establish that peptide or protein binding produces an anticancer effect.
Compound 2 is therefore best understood as a platinum compound with a different reaction profile in this test, not as a proven alternative to DNA-targeting treatment. The next step is to determine whether its lower DNA reactivity and any peptide or protein interactions can be reproduced in more complex biological systems.
Paper data and sources
Original title: All Platinum(II) Ions Are Equal, but Some React Differently: Insights Into the Biomolecular Reactivity of Platinum(II)-Based Anticancer Agents.
Authors: Andrea Cucchiaro, Monika Cziferszky
Journal/Repository: Bioinorganic chemistry and applications
Status: Peer-reviewed
First online: 2026-08-20
DOI: 10.1155/bca/9865583
Original paper